HOME >> BIOLOGY >> NEWS
AVAX Technologies' M-Vax™ cancer vaccine induces T cell mediated immune reactions in patients with metastatic melanoma

AVAX Technologies, Inc. (NASDAQ: AVXT) today announced the presentation of data at the 91st Annual Meeting of the American Association for Cancer Research (AACR), which indicate that M-Vax™, a cancer vaccine made from the patient's own tumor cells, induces T cell infiltration of metastatic sites. T cells are the class of white blood cells believed to be instrumental in fighting cancer cells. The presentation, entitled "T cell receptor structure of lymphocytes infiltrating melanoma metastases after administration of autologous, dinitrophenyl-modified vaccine," showed data that continue to validate earlier results demonstrating that M-Vax elicits an immune response in patients with advanced disease. Most importantly, the data suggest that the vaccine induces the expansion of novel T cell clones, targeted against the tumor. These T cells are involved in controlling immune reactions and may also be the principal agents of anti-tumor effects. The studies were conducted by David Berd, M.D., inventor of the AC Vaccine™ technology and Professor of Medicine, Thomas Jefferson University.

The data reported represent a follow up of earlier work published in 1997 that demonstrate that certain dominant T cell receptor families were identified in nine out of ten melanoma tumors removed from advanced patients who had an immunologic response to M-Vax. In contrast, examination of control specimens - tumors removed from patients before treatment with M-Vax or T cells extracted from blood showed a random pattern of T cells, which would be expected in the absence of an anti-cancer immune response. These findings suggest that treatment with M-Vax results in the expansion of certain groups of T cells that were not present before treatment, and that these T cells specifically target the tumor.

"In previous studies we found that M-Vax caused the development of inflammation in the tumors," Dr. Berd explained. Dr. Berd said that the tumors bec
'"/>

Contact: Olga Fleming
ofleming@cpronline.com
201-641-2408 ext 34
AVAX Technologies, Inc.
3-Apr-2000


Page: 1 2

Related biology news :

1. Palatin Technologies PT-141 increases sexual behavior in female animals
2. AVAX Technologies M-Vax™ cancer vaccine extends five-year overall survival in patients with lymph node metastatic melanoma
3. AVAX Technologies O-Vax™ cancer vaccine induces positive immunological and clinical outcomes in patients with advanced ovarian cancer
4. AVAX Technologies AC Vaccine™ improves relapse-free survival
5. Leader in cancer treatment and prevention research honored
6. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
7. Chemical derived from vitamin-E shows early promise as cancer drug
8. New molecular link key to cellular proteins involved in cancer progression, other diseases
9. Phase II trials of second-generation antisense cancer drug planned following successful early study
10. Trial shows which brain cancer patients benefit from temozolomide
11. Genetic differences might help distinguish thyroid cancers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... PBI-Gordon Corporation ... and Agricultural Sales. , Doug began his career at PBI-Gordon in February 1988, ... in a wide variety of roles, ranging from customer service to national product manager, ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nutrafol®, a first-to-market ... treat hormonal and stress related hair loss. With patent-pending formulas for both female ... opinion leaders in the medical and salon channels nationwide. , Dermatologists, Plastic ...
(Date:5/3/2016)... India , May 3, 2016 /PRNewswire/ ... (DNA Chip (Genomics, Drug Discovery, Gene Expression) ... End user (Academics Institutes, Diagnostics Centers), Fabrication ... published by MarketsandMarkets, the market is expected ... from USD 7.63 Billion in 2015, growing ...
(Date:5/3/2016)... CA (PRWEB) , ... May 03, 2016 , ... ... Playbook™ enterprise talent development, skill-building and compliance training platform on mobile devices, ... training course: Overview of Regulatory Requirements for Medical Devices. The course is essential ...
Breaking Biology Technology:
Cached News: